Previous 10 | Next 10 |
Aurinia Pharmaceuticals has seen a nice surge in its stock price over the past month after reporting better-than-expected initial sales for its flagship product LUPKYNIS. Can the rally continue? We take a look at recent results, analyst commentary and other factors to attempt to ...
Motley Fool investors are on the hunt these days for cheap Canadian stocks to buy. But what makes a stock cheap? For me, it means a company’s fundamentals are strong, but the share price doesn’t reflect the past or future performance of the stock. On the TSX today, there a...
Motley Fool investors might think that the healthcare industry already had its hay day. In fact, almost the exact opposite is true. While certain areas of the healthcare industry thrived during the pandemic, others completely sunk. I’m going to look at healthcare companies that did w...
Cheap stocks are what every Motley Fool investor wants . But what’s great is when you can find cheap stocks that provide long-term growth opportunities. On top of that, we have the pandemic to consider today. So, investors will also want to find cheap stocks that offer a stab...
- Assets expand immunology portfolio to include B-cell therapy (BAFF/APRIL) and macrophage modulation - - IND-enabling studies are ongoing and will support the transition of these assets to clinical development in 2022/2023 - Aurinia Pharmaceuticals Inc. ...
Retirement is the goal everyone wishes to reach. One day, Motley Fool investors can stop working and simply live off your hard work. But that also means investing, and that’s when retirement becomes a numbers game. How much exactly will you need to be able to feel comfortable for the...
The TSX Composite is back. After a drop during July, the index now trades at all-time highs yet again, allowing Canadians to feel like we are indeed on the verge of an economic recovery. But I wouldn’t be too quick to jump on that recovery bandwagon . While there is hope...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the Virtual BTIG Annual Biotech Conference on Tuesday, August 10, 2021 at 2:50 p.m. ET. In order to part...
The stock of Aurinia Pharmaceuticals (NASDAQ: AUPH) was surging today after the company's second-quarter earnings call. A positive outlook for Lupkynis, its recently launched drug for lupus nephritis (LN), encouraged investors to drive the stock 21.5% higher as of 1:08 p.m. EDT on F...
Gainers: Kaixin (NASDAQ:KXIN) +50%. Sphere 3D (NASDAQ:ANY) +42%. Westport Fuel Systems (NASDAQ:WPRT) +25%. SCWorx (NASDAQ:WORX) +24%. Aurinia Pharmaceuticals (NASDAQ:AUPH) +22%. LiveRamp Holdings (NYSE:RAMP) +20%. Grid Dynamics (NASDAQ:GDYN) +19%. Bit Digital (NASDAQ:BTBT) +19%. Switch (NYSE:...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...